Prestige Consumer Healthcare Inc. (PBH) AI Stock Analysis
PBH AI stock analysis summary
AI ResearchPrestige Consumer Healthcare Inc. (PBH) markets and distributes over-the-counter health and personal care products across North America and internationally. In FY2026, the company generated $1.09B in revenue with a net income of $190.3M, while carrying $2.06B in total debt. Trailing twelve-month revenue reached $1.10B with an operating margin of 20.8%.
- Market cap
- $2.36B
- Revenue (TTM)
- $1.10B
- P/E
- 14.0x fwd 10.5x
- 1Y return
- -19.2% S&P 500 16.8%
- Avg. target
- $67.80 35.8% vs last close
Bull case
- The stock trades at a forward P/E of 10.5x, well below the median of its US-listed Healthcare peers at 17.3x.
- Free cash flow generation remained resilient at $246.4M in FY2026, supporting $156.3M in share buybacks during the year.
- Analysts maintain an average price target of $67.80, suggesting a 35.8% potential upside from the closing price of $49.92.
Bear case
- Total debt reached $2.06B as of June 30, 2026, resulting in a net debt balance of $1.97B against cash and short-term investments of $89.1M.
- In the latest quarter ended June 30, 2026, quarterly earnings fell 35.8% year-over-year.
- Prestige Consumer Healthcare shares fell 19.2% over the trailing one-year period, trailing the S&P 500 gain of 16.8%.
What Prestige Consumer Healthcare does
Prestige Consumer Healthcare Inc., founded in 1996 and based in Tarrytown, New York, develops, manufactures, markets, and distributes over-the-counter health and personal care products across the United States and internationally. It operates through two principal segments: North American OTC Healthcare and International OTC Healthcare. Its brand portfolio includes BC/Goody's analgesic powders, Boudreaux's Butt Paste, Chloraseptic sore throat remedies, Clear Eyes, Compound W wart removal, DenTek oral care, Debrox ear wax removal aids, and Dramamine motion sickness remedies. The company distributes its products via mass merchandisers, drugstores, grocery stores, dollar stores, convenience stores, club stores, and online channels.
Growth and profitability
Prestige Consumer Healthcare registered a 5-year revenue compound annual growth rate of 2.9% from FY2021 to FY2026. Annual revenue moved from $1.09B in FY2022 to $1.13B in FY2023 and FY2024, reaching $1.14B in FY2025 before declining 4.3% to $1.09B in FY2026. Gross margin fell from 57.1% in FY2022 to 52.8% in FY2026, while operating margin went from 30.4% in FY2022 to 28.4% in FY2026. Annual net income was -$82.3M in FY2023 but rebounded to $190.3M in FY2026 with an EPS of $4.18. In the latest quarter ended June 30, 2026, quarterly revenue grew 6.5% year-over-year, while quarterly earnings dropped 35.8%.
Balance sheet and cash flow
As of June 30, 2026, Prestige Consumer Healthcare held $89.1M in cash and short-term investments against total debt of $2.06B, resulting in net debt of $1.97B. Shareholders' equity stood at $1.92B, producing a debt-to-equity ratio of 1.08, while total assets were $4.57B and the current ratio was 3.23. During FY2026, the company generated $257.6M in operating cash flow and $246.4M in free cash flow. Capital expenditures totaled $11.2M, and the company directed $156.3M to share buybacks, contributing to a 5-year share count change of -6.5%.
Valuation and performance
At a share price of $49.92 as of October 16, 2026, Prestige Consumer Healthcare has a market capitalization of $2.36B and an enterprise value of $4.24B. The stock trades at a trailing P/E of 14.0x and a forward P/E of 10.5x, compared to 24.6x and 17.3x for the median of its US-listed Healthcare peers. Its price-to-sales ratio is 2.1x versus the peer median of 4.1x, while its EV/EBITDA of 13.6x exceeds the peer median of 12.0x. Over the past year, the stock fell 19.2%, underperforming the S&P 500 benchmark return of 16.8%.
What analysts expect
Wall Street analysts cover Prestige Consumer Healthcare with 4 Strong Buy, 1 Buy, and 2 Hold ratings, with no Sell or Strong Sell ratings. The mean price target is $67.80, representing a 35.8% upside relative to the October 16, 2026 closing price of $49.92. For the current fiscal year ending March 31, 2027, consensus estimates project revenue of $1.27B and EPS of $4.57, reflecting 4.3% EPS growth. Over the last 4 quarters, the company beat EPS estimates 1 time. The next earnings date is November 5, 2026.
Key risks and what to watch
- High leverage is evident with total debt of $2.06B compared to shareholders' equity of $1.92B and a debt-to-equity ratio of 1.08.
- Gross margin contracted from 57.1% in FY2022 to 52.8% in FY2026, reflecting margin pressure over multi-year periods.
- Short interest remains elevated, with short percent of float standing at 11.8%.
- Prestige Consumer Healthcare beat EPS estimates in only 1 of the last 4 quarters, pointing to recent execution inconsistency.
AI-generated research summary. Written with AI from Quotelinks data as of October 16, 2026 and checked so every figure matches that data. For information only, not investment advice. Disclaimer
About this PBH AI stock analysis
This page is an AI-written research summary of Prestige Consumer Healthcare Inc. (PBH). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.
Related: PBH income statement, PBH balance sheet, PBH key metrics, PBH analyst forecast, PBH chart. See the PBH stock overview for the latest quote and news.
PBH AI stock analysis FAQ
Does Prestige Consumer Healthcare pay a dividend?
Prestige Consumer Healthcare does not pay a dividend based on current disclosures, directing cash flow toward capital expenditures of $11.2M and share buybacks of $156.3M in FY2026.
What is Prestige Consumer Healthcare's debt position?
As of June 30, 2026, Prestige Consumer Healthcare held $89.1M in cash and short-term investments alongside total debt of $2.06B, resulting in net debt of $1.97B and a debt-to-equity ratio of 1.08.
What are analysts forecasting for PBH earnings?
For the fiscal year ending March 31, 2027, analysts forecast EPS of $4.57 on revenue of $1.27B, followed by projected EPS of $5.08 on revenue of $1.35B for the next fiscal year.
How has PBH stock performed compared to the broader market?
Over the trailing 1-year period, PBH returned -19.2% while the S&P 500 gained 16.8%, and over 5 years PBH returned -14.5% compared to an 83.0% gain for the benchmark index.